MADDEN SECURITIES Corp purchased a new stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Rating) in the fourth quarter, according to its most recent disclosure with the SEC. The firm purchased 36 shares of the biopharmaceutical company’s stock, valued at approximately $26,000.
A number of other large investors have also added to or reduced their stakes in REGN. Price T Rowe Associates Inc. MD grew its holdings in Regeneron Pharmaceuticals by 92.5% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 1,694,308 shares of the biopharmaceutical company’s stock worth $1,001,556,000 after acquiring an additional 813,967 shares in the last quarter. Renaissance Technologies LLC grew its holdings in Regeneron Pharmaceuticals by 108.3% during the 2nd quarter. Renaissance Technologies LLC now owns 583,062 shares of the biopharmaceutical company’s stock worth $344,665,000 after acquiring an additional 303,200 shares in the last quarter. Massachusetts Financial Services Co. MA acquired a new position in Regeneron Pharmaceuticals during the 3rd quarter worth $136,678,000. FMR LLC grew its holdings in Regeneron Pharmaceuticals by 1.9% during the 2nd quarter. FMR LLC now owns 10,176,199 shares of the biopharmaceutical company’s stock worth $6,015,457,000 after acquiring an additional 193,175 shares in the last quarter. Finally, Great West Life Assurance Co. Can acquired a new position in Regeneron Pharmaceuticals during the 3rd quarter worth $116,414,000. 84.25% of the stock is owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
Several research analysts have weighed in on the stock. Wells Fargo & Company raised their price objective on shares of Regeneron Pharmaceuticals from $800.00 to $860.00 and gave the stock an “overweight” rating in a report on Friday, February 17th. JPMorgan Chase & Co. raised shares of Regeneron Pharmaceuticals from a “neutral” rating to an “overweight” rating and set a $850.00 price target for the company in a report on Friday, January 20th. SVB Leerink lifted their price target on shares of Regeneron Pharmaceuticals from $770.00 to $834.00 and gave the company a “market perform” rating in a report on Monday, February 6th. Robert W. Baird lifted their price target on shares of Regeneron Pharmaceuticals from $670.00 to $756.00 in a report on Monday, February 6th. Finally, StockNews.com began coverage on shares of Regeneron Pharmaceuticals in a report on Thursday. They issued a “buy” rating for the company. One research analyst has rated the stock with a sell rating, four have issued a hold rating and fifteen have given a buy rating to the company. Based on data from MarketBeat, Regeneron Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $815.38.
Regeneron Pharmaceuticals Stock Down 0.3 %
Regeneron Pharmaceuticals (NASDAQ:REGN – Get Rating) last released its quarterly earnings results on Friday, February 3rd. The biopharmaceutical company reported $12.56 EPS for the quarter, topping analysts’ consensus estimates of $8.18 by $4.38. Regeneron Pharmaceuticals had a net margin of 35.64% and a return on equity of 22.87%. The company had revenue of $3.41 billion for the quarter, compared to the consensus estimate of $3.11 billion. During the same period in the previous year, the firm earned $23.72 EPS. Regeneron Pharmaceuticals’s revenue was down 31.1% on a year-over-year basis. On average, analysts forecast that Regeneron Pharmaceuticals, Inc. will post 34.22 earnings per share for the current fiscal year.
Insider Buying and Selling
In related news, EVP Marion Mccourt sold 1,100 shares of the business’s stock in a transaction that occurred on Wednesday, March 1st. The shares were sold at an average price of $759.89, for a total value of $835,879.00. Following the sale, the executive vice president now directly owns 20,803 shares in the company, valued at approximately $15,807,991.67. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, EVP Marion Mccourt sold 1,100 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Wednesday, March 1st. The shares were sold at an average price of $759.89, for a total value of $835,879.00. Following the transaction, the executive vice president now directly owns 20,803 shares of the company’s stock, valued at $15,807,991.67. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Arthur F. Ryan sold 100 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Wednesday, March 1st. The stock was sold at an average price of $762.50, for a total transaction of $76,250.00. Following the completion of the transaction, the director now directly owns 19,147 shares in the company, valued at $14,599,587.50. The disclosure for this sale can be found here. Insiders have sold 27,273 shares of company stock worth $21,189,979 in the last ninety days. 8.99% of the stock is currently owned by corporate insiders.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies.
Read More
- Get a free copy of the StockNews.com research report on Regeneron Pharmaceuticals (REGN)
- MarketBeat Week in Review – 3/13 – 3/17
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
